An Emerging REMS Dilemma: Qnexa, Truvada – and Korlym
This article was originally published in RPM Report
Executive Summary
Two high-profile applications pose a thorny dilemma for FDA: how to impose a REMS for a new indication without restricting access for already approved uses where restrictions are not appropriate. That same issue didn’t seem to slow the agency down on a recent approval decision involving a very controversial ingredient.
You may also be interested in...
Gilead Builds Adherence Trial and Behavior Profiling Data Into Truvada PrEP Approval
FDA approval of Gilead’s Truvada for pre-exposure prophylaxis generated national news in advance of the major HIV/AIDS international scientific meeting starting in Washington one week later. As part of the final negotiations to get the approval done in time for the news window, FDA and Gilead worked out an interesting arrangement on post-marketing studies that has broad implications for future sponsors.
FDAAA Impact Analysis (Year 4): The REMS Retreat Continues - For Now
As the fifth year of the REMS era begins, FDA is imposing mandatory programs less frequently than it did even in the first year after the law creating formal risk management plans took effect. But there are some new trends to watch, including the evolution of REMS classes and the emergence of products with REMS-in-waiting.
Two Indications, One REMS: FDA Panel Debates Restricted Access For Truvada In PrEP
FDA did not ask its Antiviral Drugs Advisory Committee whether Gilead’s proposed REMS for pre-exposure prophylaxis should include restricted distribution, but it still got an earful on the subject from some vocal panel members, who said prescribing should be limited only to individuals with documentation of a negative HIV test. Agency staff, however, said such an approach was impractical due to Truvada’s unrestricted availability for HIV treatment.